Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tests if asthma drug can stop symptoms Long-Term

NCT ID NCT07214753

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 4 times

Summary

This study follows 335 adults with severe eosinophilic asthma who are taking benralizumab. Researchers want to see if the drug helps patients achieve partial or complete clinical remission—meaning fewer symptoms, no need for steroid pills, and better lung function—over 12 to 24 months. The goal is to understand how well the treatment controls the disease in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 335 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Severe eosiniphilic asthma patients treated with benralizumab as per clinical practices

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (≥ 18 years old) diagnosed with severe uncontrolled eosinophilic asthma. * Benralizumab has been prescribed according to the approved label and local reimbursement criteria * Provision of signed Informed Consent Form (ICF) prior to any study-related activities * Benralizumab has been initiated within 7 days prior to study enrollment or is planned to be initiated within 7 days after enrollment (in the latter case, provided that the decision to prescribe benralizumab is made prior to the decision to enroll the patient in the study). Exclusion Criteria: * Benralizumab treatment within the 12 months prior to study enrollment and up to 8 days before enrollment * Previous participation (in the 12 months before enrollment), current participation or plan to participate within the follow up period to any other clinical trial. * Contraindication to benralizumab as per current Summary of Product Characteristics (SmPC). * Pregnant or lactating women. * patients with any clinical condition that may interfere with the subject's ability to cooperate and comply with the study procedures based on the Investigator's judgement. * Previous or concomitant use of omalizumab, reslizumab, dupilumab, tezepelumab or mepolizumab without washout period as per clinical practice

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Severe eosinophilic asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pulmonary eosinophilia T2-high asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Severe eosinophilic asthma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    28 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    NOT_YET_RECRUITING

    Salerno, Battipaglia, 84031, Italy

  • Research Site

    NOT_YET_RECRUITING

    Padova, Cittadella, 35013, Italy

  • Research Site

    RECRUITING

    Teramo, Giulianova, 64021, Italy

  • Research Site

    RECRUITING

    Treviso, Montebelluna, 31044, Italy

  • Research Site

    RECRUITING

    Varese, Tradate, 21049, Italy

  • Research Site

    RECRUITING

    Bari, 70120, Italy

  • Research Site

    NOT_YET_RECRUITING

    Bergamo, 24127, Italy

  • Research Site

    RECRUITING

    Bologna, 40138, Italy

  • Research Site

    NOT_YET_RECRUITING

    Bologna, 40139, Italy

  • Research Site

    NOT_YET_RECRUITING

    Brescia, 25123, Italy

  • Research Site

    NOT_YET_RECRUITING

    Catania, 95123, Italy

  • Research Site

    RECRUITING

    Catanzaro, 88100, Italy

  • Research Site

    NOT_YET_RECRUITING

    Florence, 50134, Italy

  • Research Site

    NOT_YET_RECRUITING

    Foggia, 71122, Italy

  • Research Site

    NOT_YET_RECRUITING

    Messina, 98124, Italy

  • Research Site

    RECRUITING

    Milan, 20142, Italy

  • Research Site

    RECRUITING

    Modena, 41125, Italy

  • Research Site

    RECRUITING

    Naples, 80131, Italy

  • Research Site

    NOT_YET_RECRUITING

    Naples, 80131, Italy

  • Research Site

    NOT_YET_RECRUITING

    Padova, 35128, Italy

  • Research Site

    RECRUITING

    Palermo, 90127, Italy

  • Research Site

    NOT_YET_RECRUITING

    Pavia, 27100, Italy

  • Research Site

    NOT_YET_RECRUITING

    Roma, 00152, Italy

  • Research Site

    RECRUITING

    Roma, 00189, Italy

  • Research Site

    NOT_YET_RECRUITING

    Sassari, 07100, Italy

  • Research Site

    NOT_YET_RECRUITING

    Siena, 53100, Italy

  • Research Site

    RECRUITING

    Torino, 10128, Italy

  • Research Site

    NOT_YET_RECRUITING

    Verona, 37134, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.